CTI Clinical Trial and Consulting Services
(CTI), a global, privately held, full-service contract research organization announces the acquisition of
S2 Statistical Solutions
(S2). S2, a health outcomes and health economics organization, focuses on the power of analytics through data mining and economic research. S2 specializes in generating and interpreting evidence from large databases and then publishing it in the most effective, high-impact venues, including various peer reviewed publications. S2 has been partnering with pharmaceutical, medical device, and diagnostic companies for over a decade, providing innovative outcome and economic analyses, models, visualization programs, systematic literature reviews, and meta analyses. Dr. Candace Gunnarsson, the founder of S2, will be joining CTI along with her entire team.
“I am very excited to combine forces with CTI and I know that we will be able to achieve great things together. Our principles, work ethic and expertise truly complement the CTI Team,” states Dr. Candace Gunnarsson, President of S2.
According to Lynn Fallon, Executive Vice President and President, Consulting Services at CTI, “The S2 team members are incredibly accomplished with top-ranked scientists, health economists, and statisticians, and will join Dr. William Irish, CTI’s Vice President of Health Outcomes and Biostatistics, as well as the rest of our team at CTI. We firmly believe that health outcomes and economics are critically important to both our biotechnology and pharmaceutical clients. This merger strengthens our service offerings from the early development stages of drugs and devices through Phase 3 and commercialization. Investors often require companies to build economic models to provide product valuation, even in early development. Health economics is also proving particularly important to the many orphan disease programs that CTI is leading.”
The terms of the acquisition were not disclosed. Plante Moran and Fifth Third Bank provided support to CTI, while Graydon, Head and Ritchey assisted S2.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.